Bio-bedst Aps

Leo-pharma A/s

Mogens Winkel Madsen

Sune Allan Petersen

Anders Falk Vikbjerg

Fredrik Melander

Morten Just Petersen

Lone Stengelsh&oslash;j Olsen

The present invention relates to medical use of liposomes, more particular the first medical use of sPLA2 hydrolysable liposomes. Such liposomes may be used for targeted delivery of therapeutic agents to cancerous tissue and in such embodiments; the therapeutic agents are typically small molecule antitumor agents. Other aspects of the inventions relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastrointestinal toxicity of a therapeutic agent. Yet another aspect of the present invention relate to methods of prolonging the therapeutic effect of a therapeutic agent.

Medical use of sPLA2 hydrolysable liposomes

The present invention provides a composition comprising a sPLA2 hydrolysable liposome, an exterior solution, and an interior solution within the liposome, &#x2014;wherein the concentration of osmolytes is higher in the interior solution than in the exterior solution. The composition improves storage stability of sPLA2 hydrolysable liposomes, in particular at when stored at 2-8 degrees Celsius. The liposome preferably encapsulates cisplatin. The invention also provides methods of preparing the composition of the invention.

SPLA2 hydrolysable liposomes with improved storage stability

Method of modulating NF-kB activity

Growing community of inventors

Virum, Denmark

Mogens Winkel Madsen